Healthcare May 24, 2022 09:45 AM (GMT+8) · EqualOcean
Recently, according to the information of the Hong Kong stock exchange, Temasek, a famous sovereign fund in Singapore, reduced its holdings of 3.654 million shares of Cinda Biology (01801. HK) on May 17, with an average price of 18.668 yuan per share, and the shareholding ratio decreased from 9.11% to 8.86%. Founded in 2011, Xinda biology is committed to developing, producing and selling new monoclonal antibodies for the treatment of major diseases such as tumors. The company was listed in Chapter 18a on the main board of Hong Kong on October 31, 2018 (Code: 01801), and then announced the removal of the "B" mark on June 22, 2020. Cinda bio raised US $485 million when it was listed, creating the largest IPO record of unprofitable biotechnology enterprises in the history of the world. The issue price of the company when it was listed in Hong Kong was HK $13.98 per share. As of the closing of May 23, it was HK $22.55 per share, with a total market value of about HK $32.4 billion.